

Miguel Angel Sanz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7191631/publications.pdf>

Version: 2024-02-01

588
papers

41,300
citations

9786

73
h-index

2895

190
g-index

604
all docs

604
docs citations

604
times ranked

25113
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2022, 36, 90-99.	7.2	42
2	Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. <i>Blood Advances</i> , 2022, 6, 1278-1295.	5.2	29
3	Effect of Sustainable Preharvest and Postharvest Techniques on Quality and Storability of High-Acidity "Reinette du Canada"™ Apple. <i>Horticulturae</i> , 2022, 8, 86.	2.8	0
4	Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. <i>Cancers</i> , 2022, 14, 1734.	3.7	13
5	Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study. <i>Cancers</i> , 2022, 14, 1921.	3.7	1
6	Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry. <i>Cancers</i> , 2022, 14, 2342.	3.7	4
7	Effect of Fruit Weight and Fruit Locule Number in Bell Pepper on Industrial Waste and Quality of Roasted Pepper. <i>Horticulturae</i> , 2022, 8, 455.	2.8	0
8	Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 2817.	3.7	0
9	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 1389-1398.	2.4	10
10	Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?. <i>Leukemia</i> , 2021, 35, 1571-1585.	7.2	12
11	Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2021, 106, 114-125.	2.2	2
12	Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. <i>Bone Marrow Transplantation</i> , 2021, 56, 1272-1280.	2.4	18
13	Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 659-668.	1.3	10
14	History of Acute Promyelocytic Leukemia. <i>Clinical Hematology International</i> , 2021, 3, 142.	1.7	10
15	Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. <i>Blood Advances</i> , 2021, 5, 760-770.	5.2	18
16	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2358-2370.	7.2	31
17	A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2003-2014.	4.1	16
18	Central Nervous System Involvement in Epstein–Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 261.e1-261.e7.	1.2	4

#	ARTICLE	IF	CITATIONS
19	Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients?. <i>Transplant Infectious Disease</i> , 2021, 23, e13602.	1.7	9
20	Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia. <i>Pharmacogenetics and Genomics</i> , 2021, Publish Ahead of Print, 133-139.	1.5	2
21	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. <i>EJHaem</i> , 2021, 2, 236-248.	1.0	4
22	Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 614215.	2.8	7
23	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021, 35, 2539-2551.	7.2	51
24	Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. <i>European Journal of Haematology</i> , 2021, 106, 724-733.	2.2	1
25	A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients. <i>Annals of Hematology</i> , 2021, 100, 1497-1508.	1.8	7
26	A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms. <i>Cancers</i> , 2021, 13, 1947.	3.7	5
27	Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 311.e1-311.e10.	1.2	4
28	Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-versus-host disease: Pharmacoeconomic assessment of hospital resource use in Spain. <i>Journal of Clinical Apheresis</i> , 2021, 36, 612-620.	1.3	2
29	The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. <i>Cancers</i> , 2021, 13, 2458.	3.7	7
30	Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. <i>Leukemia and Lymphoma</i> , 2021, 62, 2727-2736.	1.3	0
31	Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. <i>Leukemia and Lymphoma</i> , 2021, 62, 2928-2938.	1.3	21
32	Recomendaciones del Grupo Español de PTI para el diagnóstico, tratamiento y seguimiento de pacientes con trombocitopenia inmune. <i>Medicina Clínica</i> , 2021, 157, 191-198.	0.6	10
33	Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. <i>HemaSphere</i> , 2021, 5, e617.	2.7	10
34	Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombocytopenia. <i>Medicina Clínica (English Edition)</i> , 2021, 157, 191-198.	0.2	0
35	Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. <i>Haematologica</i> , 2021, 106, 3079-3089.	3.5	15
36	Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens. <i>Scientific Reports</i> , 2021, 11, 20745.	3.3	11

#	ARTICLE	IF	CITATIONS
37	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. <i>Blood Cancer Journal</i> , 2021, 11, 167.	6.2	11
38	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6233.	12.8	17
39	Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 5677.	3.7	8
40	Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group. <i>Blood</i> , 2021, 138, 1302-1302.	1.4	0
41	Patterns of Salvage Therapy in Patients with Acute Myeloid Leukemia Treated Upfront with Azacitidine or Decitabine: Results from the Pethema AML Registry. <i>Blood</i> , 2021, 138, 1255-1255.	1.4	0
42	Venetoclax Therapy in a Heavily Treated Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia: Update of the Pethema Registry Experience. <i>Blood</i> , 2021, 138, 2325-2325.	1.4	0
43	Impact of Sociodemographic and Clinical Factors on the Survival of Patients with Acute Myeloid Leukemia: A Multicenter Experience in Colombia, on Behalf of ACHO's Renehoc-Pethema Investigators. <i>Blood</i> , 2021, 138, 3374-3374.	1.4	1
44	Integrated Multidimensional Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) to Reconstruct Evolutionary Patterns from Dysplasia to Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 520-520.	1.4	0
45	Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry. <i>Blood</i> , 2021, 138, 1256-1256.	1.4	0
46	Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 105-113.	0.4	3
47	Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 83-87.	2.0	3
48	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 358-366.	2.0	36
49	Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism. <i>Haematologica</i> , 2020, 105, 1559-1566.	3.5	32
50	High Heterogeneity of Multidrug-Resistant <i>Enterobacteriaceae</i> Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous β -Lactams. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	3
51	Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. <i>European Journal of Haematology</i> , 2020, 104, 162-169.	2.2	6
52	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	5.2	34
53	Advances in the management of coagulopathy in acute promyelocytic leukemia. <i>Thrombosis Research</i> , 2020, 191, S63-S67.	1.7	28
54	Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia. <i>Cancers</i> , 2020, 12, 3134.	3.7	7

#	ARTICLE	IF	CITATIONS
55	Community acquired respiratory virus infections in adult patients undergoing umbilical cord blood transplantation. Bone Marrow Transplantation, 2020, 55, 2261-2269.	2.4	3
56	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transplantation, 2020, 55, 2147-2159.	2.4	24
57	Genotypic and Phenotypic Characteristics of Acute Promyelocytic Leukemia Translocation Variants. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 189-201.	0.9	18
58	Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene. Cancers, 2020, 12, 624.	3.7	77
59	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. Scientific Reports, 2020, 10, 10315.	3.3	5
60	Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide in an International Collaborative Study. Leukemia, 2020, 34, 2333-2341.	7.2	20
61	The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation. Journal of Infection, 2020, 80, 333-341.	3.3	7
62	Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype. Scientific Reports, 2020, 10, 5904.	3.3	8
63	Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols. European Journal of Haematology, 2020, 105, 138-147.	2.2	12
64	Acute Promyelocytic Leukemia during Pregnancy: A Systematic Review of the Literature. Cancers, 2020, 12, 968.	3.7	12
65	MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients. International Journal of Molecular Sciences, 2020, 21, 2714.	4.1	9
66	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood, 2020, 135, 371-380.	1.4	127
67	PLZF-RAR α , NPM1-RAR α , and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review. Cancers, 2020, 12, 1313.	3.7	20
68	Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry. Blood, 2020, 136, 25-27.	1.4	3
69	Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The Pethema Registry Experience. Blood, 2020, 136, 2-3.	1.4	0
70	Validation of the High-Risk Prognostic Score Defined By the Presence of Mutations in NRAS or TP53 in a Cohort of 497 Patients with Acute Myeloid Leukemia. Blood, 2020, 136, 4-5.	1.4	0
71	Immunohaematological events related to changes in haematic and seric ABO group in patients undergoing haematopoietic stem cell transplantation with major ABO mismatch. Transfusion Medicine, 2019, 29, 136-137.	1.1	1
72	Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. Leukemia and Lymphoma, 2019, 60, 142-150.	1.3	38

#	ARTICLE	IF	CITATIONS
73	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. <i>Blood</i> , 2019, 134, 951-959.	1.4	21
74	Dexamethasone does not prevent malignant cell reintroduction in leukemia patients undergoing ovarian transplant: risk assessment of leukemic cell transmission by a xenograft model. <i>Human Reproduction</i> , 2019, 34, 1485-1493.	0.9	11
75	Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus. <i>Annals of Hematology</i> , 2019, 98, 2467-2483.	1.8	9
76	Challenges in Clinical Metaproteomics Highlighted by the Analysis of Acute Leukemia Patients with Gut Colonization by Multidrug-Resistant Enterobacteriaceae. <i>Proteomes</i> , 2019, 7, 2.	3.5	71
77	Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 197-218.	3.1	15
78	A viral RNA motif involved in signaling the initiation of translation on non-AUG codons. <i>Rna</i> , 2019, 25, 431-452.	3.5	8
79	Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1818-1824.	2.0	29
80	Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. <i>Annals of Hematology</i> , 2019, 98, 2081-2088.	1.8	16
81	Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation. <i>European Journal of Haematology</i> , 2019, 103, 172-177.	2.2	5
82	Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. <i>Leukemia and Lymphoma</i> , 2019, 60, 2720-2732.	1.3	2
83	RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib. <i>Acta Haematologica</i> , 2019, 142, 92-97.	1.4	6
84	Detection of plasmid-mediated colistin resistance, mcr-1 gene, in Escherichia coli isolated from high-risk patients with acute leukemia in Spain. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 605-609.	1.7	15
85	DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019016.	1.3	3
86	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , 2019, 133, 1630-1643.	1.4	393
87	Genomic characterization of Citrobacter freundii strains coproducing OXA-48 and VIM-1 carbapenemase enzymes isolated in leukemic patient in Spain. <i>Antimicrobial Resistance and Infection Control</i> , 2019, 8, 167.	4.1	13
88	Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 228-240.	2.8	24
89	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 1146-1155.	1.3	12
90	Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain. <i>PharmacoEconomics - Open</i> , 2019, 3, 229-235.	1.8	3

#	ARTICLE	IF	CITATIONS
91	A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. <i>Leukemia Research</i> , 2019, 76, 1-10.	0.8	15
92	Validation of a multivariable prediction model for postâ€engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients. <i>Mycoses</i> , 2019, 62, 418-427.	4.0	3
93	An analysis of the impact of CD56 expression in <i>de novo</i> acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. <i>Leukemia and Lymphoma</i> , 2019, 60, 1030-1035.	1.3	9
94	Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen. <i>European Journal of Haematology</i> , 2019, 102, 331-340.	2.2	4
95	Acute Myeloid Leukemia in Adults. , 2019, , 507-521.		4
96	A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group. <i>Blood</i> , 2019, 134, 648-648.	1.4	1
97	Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry. <i>Blood</i> , 2019, 134, 1321-1321.	1.4	0
98	Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , 2019, 134, 2719-2719.	1.4	0
99	Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers. <i>Blood</i> , 2019, 134, 2352-2352.	1.4	3
100	Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial. <i>Blood</i> , 2019, 134, 3891-3891.	1.4	0
101	Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , 2019, 134, 5166-5166.	1.4	0
102	Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo EspaÃ±ol De Trasplante de Medula Osea en NiÃ±os (GETMON) and the Grupo EspaÃ±ol de Trasplante Hematopoyetico (GETH). <i>Transfusion Medicine Reviews</i> , 2018, 32, 179-185.	2.0	30
103	Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. <i>Annals of Hematology</i> , 2018, 97, 1115-1153.	1.8	81
104	Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes. <i>Haematologica</i> , 2018, 103, e400-e403.	3.5	9
105	A phase Iâ€II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. <i>Annals of Hematology</i> , 2018, 97, 763-772.	1.8	39
106	Hematopoietic Stem Cell Transplantation in APL. , 2018, , 171-177.		0
107	Prognostic Factors in APL. , 2018, , 87-98.		0
108	Special Situations in APL. , 2018, , 203-210.		0

#	ARTICLE	IF	CITATIONS
109	Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. <i>Experimental Hematology</i> , 2018, 62, 24-32.	0.4	15
110	The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 180, 915-918.	2.5	2
111	Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy. <i>Pharmacogenomics Journal</i> , 2018, 18, 301-307.	2.0	18
112	Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. <i>Leukemia</i> , 2018, 32, 21-29.	7.2	24
113	Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). <i>Leukemia and Lymphoma</i> , 2018, 59, 1113-1120.	1.3	23
114	Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2018, 97, 161-167.	1.8	22
115	Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. <i>Cancers</i> , 2018, 10, 436.	3.7	8
116	The modular network structure of the mutational landscape of Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2018, 13, e0202926.	2.5	5
117	The Initiation Factors eIF2, eIF2A, eIF2D, eIF4A, and eIF4G Are Not Involved in Translation Driven by Hepatitis C Virus IRES in Human Cells. <i>Frontiers in Microbiology</i> , 2018, 9, 207.	3.5	31
118	Anti-D Alloimmunization after RhD-Positive Platelet Transfusion in RhD-Negative Women under 55 Years Diagnosed with Acute Leukemia: Results of a Retrospective Study. <i>Transfusion Medicine and Hemotherapy</i> , 2018, 45, 162-166.	1.6	8
119	Molecular remission as a therapeutic objective in acute promyelocytic leukemia. <i>Leukemia</i> , 2018, 32, 1671-1678.	7.2	44
120	Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia. <i>Current Drug Metabolism</i> , 2018, 19, 55-74.	1.2	22
121	Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial. <i>Blood</i> , 2018, 132, 433-433.	1.4	2
122	Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603). <i>Blood</i> , 2018, 132, 435-435.	1.4	3
123	Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide – an International Collaborative Study. <i>Blood</i> , 2018, 132, 80-80.	1.4	0
124	Long Term Survival Analysis of Multiple Myeloma Patients Receiving Induction Therapy+ Autologous STEM CELL Trasplantation, Comparing Velcade-Dexametasone to Alkylating Polichemotherapy As Induction Therapy. <i>Blood</i> , 2018, 132, 5764-5764.	1.4	0
125	Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. <i>Blood</i> , 2018, 132, 1533-1533.	1.4	0
126	Metformintreatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression. <i>Blood</i> , 2018, 132, 1532-1532.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Valorization of Carob's Germ and Seed Peel as Natural Antioxidant Ingredients in Gluten-Free Crackers. <i>Journal of Food Processing and Preservation</i> , 2017, 41, e12770.	2.0	33
128	Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party. <i>Journal of Hematology and Oncology</i> , 2017, 10, 31.	17.0	33
129	Isohaemagglutinin production after minor ABO incompatible umbilical cord blood transplantation. <i>Transfusion Medicine</i> , 2017, 27, 147-149.	1.1	3
130	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 836-847.	27.0	1,443
131	Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. <i>Neurological Sciences</i> , 2017, 38, 1213-1221.	1.9	40
132	Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study. <i>Hematology</i> , 2017, 22, 1-9.	1.5	5
133	Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin. <i>Annals of Hematology</i> , 2017, 96, 1077-1084.	1.8	8
134	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 454-464.	27.0	1,628
135	Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 270-274.	1.5	4
136	Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment. <i>Leukemia and Lymphoma</i> , 2017, 58, 2880-2894.	1.3	12
137	Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2017, 96, 1449-1456.	1.8	32
138	Comparison of Single Unmanipulated Umbilical Cord Blood or Co-Infusion of an Umbilical Cord Blood Graft with CD34+ Cells From a Third Party Donor in Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S123-S124.	2.0	0
139	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 424-447.	1.4	4,375
140	Infections of the Central Nervous System after Unrelated Donor Umbilical Cord Blood Transplantation or Human Leukocyte Antigen-Matched Sibling Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 134-139.	2.0	24
141	Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS). <i>Leukemia and Lymphoma</i> , 2017, 58, 1686-1693.	1.3	14
142	ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 394-399.	2.4	10
143	Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1197-1206.	1.3	33
144	Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2017, 7, 630.	6.2	11

#	ARTICLE	IF	CITATIONS
145	Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia. Clinical Case Reports (discontinued), 2017, 5, 1887-1890.	0.5	6
146	Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia. Blood Advances, 2017, 1, 1807-1814.	5.2	8
147	Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. Blood Advances, 2017, 1, 1047-1055.	5.2	6
148	<i>NEDD9</i> , an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients. Oncotarget, 2017, 8, 76003-76014.	1.8	5
149	Revealing the mutational landscape of acute promyelocytic leukemia. Translational Cancer Research, 2017, 6, S127-S130.	1.0	3
150	Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget, 2017, 8, 41620-41630.	1.8	1
151	A prognostic model for survival after salvage treatment with FLAG + gemtuzumab + azogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. British Journal of Haematology, 2016, 174, 700-710.	2.5	44
152	Pharmacogenomics and the treatment of acute myeloid leukemia. Pharmacogenomics, 2016, 17, 1245-1272.	1.3	25
153	Advances in haploidentical stem cell transplantation for hematologic malignancies. Leukemia and Lymphoma, 2016, 57, 1766-1775.	1.3	13
154	Emerging strategies for the treatment of older patients with acute myeloid leukemia. Annals of Hematology, 2016, 95, 1583-1593.	1.8	16
155	Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. Leukemia, 2016, 30, 2086-2089.	7.2	45
156	Study of the S427G polymorphism and of MYBL2 variants in patients with acute myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 429-435.	1.3	10
157	A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia. Pharmacogenomics Journal, 2016, 16, 30-40.	2.0	12
158	Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico. Biology of Blood and Marrow Transplantation, 2016, 22, 584-588.	2.0	45
159	Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis. Pharmacogenomics Journal, 2016, 16, 1-2.	2.0	9
160	Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. European Journal of Haematology, 2016, 96, 128-135.	2.2	19
161	Obesity As a Risk Factor for Acute Promyelocytic Leukemia. Results from Population and Case-Control Studies Across Western Countries and Correlation with Gene Expression in the TCGA. Blood, 2016, 128, 448-448.	1.4	3
162	The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations. PLoS ONE, 2016, 11, e0148346.	2.5	23

#	ARTICLE	IF	CITATIONS
163	Genotype and environment effects on sensory, nutritional, and physical traits in chickpea (Cicer) TJ ETQq1 1 0.784314 rgBT /Qoverlock10	0.6	0
164	Infusion of Haploidentical Stem Cell after Consolidation in Younger Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase I-II Study. Blood, 2016, 128, 1614-1614.	1.4	2
165	NCCN-IPI in Patients with Diffuse Large B CELL Lymphoma Treated with DA-R-EPOCH. Retrospective Analysis. Blood, 2016, 128, 5401-5401.	1.4	0
166	Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing. Blood, 2016, 128, 598-598.	1.4	0
167	Influence of Cytarabine Metabolic Pathway Polymorphisms in Acute Myeloid Leukemia Induction Treatment. Blood, 2016, 128, 5130-5130.	1.4	0
168	Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables. Blood, 2016, 128, 3802-3802.	1.4	0
169	Preliminary Results of the Flugaza Trial: A Phase III Randomized, Open Label Study Comparing Azacytidine Versus Fludarabine and Cytarabine (FLUGA Scheme) in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2016, 128, 4036-4036.	1.4	0
170	Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. Haematologica, 2015, 100, 1294-1300.	3.5	27
171	T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis. Haematologica, 2015, 100, 558-564.	3.5	29
172	High β 2-microglobulin/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. Blood, 2015, 126, 2302-2306.	1.4	28
173	The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 2015, 100, 683-689.	3.5	36
174	Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. British Journal of Haematology, 2015, 171, 471-477.	2.5	36
175	CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia. Haematologica, 2015, 100, e183-e185.	3.5	20
176	Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies. Pharmacogenomics Journal, 2015, 15, 109-118.	2.0	26
177	Bloodstream Infections in Adult Patients Undergoing Cord Blood Transplantation from Unrelated Donors after Myeloablative Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2015, 21, 755-760.	2.0	30
178	Quality of thawed plasma inactivated with methylene blue after 48-hour storage. Transfusion and Apheresis Science, 2015, 52, 141-142.	1.0	1
179	Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment. Revista Iberoamericana De Micologia, 2015, 32, 185-189.	0.9	4
180	Transfusion Management and Immunohematologic Complications in Liver Transplantation: Experience of a Single Institution. Transfusion Medicine and Hemotherapy, 2015, 42, 8-14.	1.6	18

#	ARTICLE	IF	CITATIONS
181	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. <i>Annals of Hematology</i> , 2015, 94, 1347-1356.	1.8	31
182	Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. <i>Leukemia</i> , 2015, 29, 1084-1091.	7.2	70
183	Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia. <i>Annals of Hematology</i> , 2015, 94, 1357-1361.	1.8	23
184	Bortezomib-based induction therapy followed by intravenous busulfan+melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 415-419.	1.3	8
185	Risk of Rh (D) alloimmunisation after Rh (D) positive platelet transfusions in patients undergoing haematopoietic stem cell transplantation. <i>Transfusion Medicine</i> , 2015, 25, 49-50.	1.1	2
186	Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis. <i>Bone Marrow Transplantation</i> , 2015, 50, 1465-1472.	2.4	33
187	Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Cancer</i> , 2015, 121, 1048-1055.	4.1	77
188	Inhibition of host protein synthesis by Sindbis virus: correlation with viral RNA replication and release of nuclear proteins to the cytoplasm. <i>Cellular Microbiology</i> , 2015, 17, 520-541.	2.1	10
189	Initiation codon selection is accomplished by a scanning mechanism without crucial initiation factors in Sindbis virus subgenomic mRNA. <i>Rna</i> , 2015, 21, 93-112.	3.5	15
190	Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score. <i>Blood</i> , 2015, 126, 2554-2554.	1.4	2
191	Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH). <i>Blood</i> , 2015, 126, 4399-4399.	1.4	3
192	Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 4842-4842.	1.4	1
193	Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 4845-4845.	1.4	1
194	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (mut): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]). <i>Blood</i> , 2015, 126, 6-6.	1.4	104
195	Validation of a Next-Generation Sequencing Panel for AML Routine Diagnosis. <i>Blood</i> , 2015, 126, 1403-1403.	1.4	0
196	Usefulness of Eltrombopag in Secondary ITP Patients in Clinical Practice. <i>Blood</i> , 2015, 126, 2263-2263.	1.4	0
197	Efficacy and Safety of Eltrombopag in Persistent and Newly Diagnosed ITP. <i>Blood</i> , 2015, 126, 4657-4657.	1.4	0
198	Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study. <i>Blood</i> , 2015, 126, 172-172.	1.4	1

#	ARTICLE	IF	CITATIONS
199	High Correlation Clinical Responses to 1st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test. <i>Blood</i> , 2015, 126, 4837-4837.	1.4	0
200	Comparative Study of Post-Transplant Lymphoproliferative Disorders after Solid Organ Transplantation Versus Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 4358-4358.	1.4	0
201	Passenger lymphocyte syndrome in liver transplant recipients: a description of 12 cases. <i>Blood Transfusion</i> , 2015, 13, 423-8.	0.4	20
202	Transfusion of ABO non-identical platelets does not influence the clinical outcome of patients undergoing autologous haematopoietic stem cell transplantation. <i>Blood Transfusion</i> , 2015, 13, 411-6.	0.4	8
203	Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia. <i>PLoS ONE</i> , 2014, 9, e100245.	2.5	7
204	Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience. <i>Bone Marrow Transplantation</i> , 2014, 49, 1084-1088.	2.4	31
205	EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. <i>Bone Marrow Transplantation</i> , 2014, 49, 397-402.	2.4	63
206	Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 378-384.	3.5	16
207	Efficient Identification of Response to Cytarabine Idarubicin in Newly Diagnosed Acute Myeloid Leukemia by a New Individualized Medicine Test Based on ex vivo Pharmacology. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S118-S119.	0.4	0
208	1st Line AML Equivalent Treatments Cytarabine Plus an Anthracyclin (Ida, Dau, Mit) Show Alternative Sensitive/Resistant Profiles in ex vivo Patient Sample Chemosensitivity; Could Personalizing be the Key Selection Criterion?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S117-S118.	0.4	0
209	Prognostic impact of <i>KMT2E</i> transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. <i>British Journal of Haematology</i> , 2014, 166, 540-549.	2.5	13
210	Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2014, 99, 1380-1386.	3.5	31
211	T Cell-Depleted Related HLA-Mismatched Peripheral Blood Stem Cell Transplantation as Salvage Therapy for Graft Failure after Single Unit Unrelated Donor Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1060-1063.	2.0	16
212	A retrospective audit of platelet transfusion in a hematology service of a tertiary-care hospital: Effectiveness of training to improve compliance with standards. <i>Transfusion and Apheresis Science</i> , 2014, 50, 228-229.	1.0	4
213	Conventional induction and post-remission therapy in APL: Have we arrived?. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 33-38.	1.7	5
214	Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. <i>Annals of Hematology</i> , 2014, 93, 299-307.	1.8	38
215	Effect of CD8+ Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1744-1750.	2.0	19
216	Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2014, 93, 43-46.	1.8	16

#	ARTICLE	IF	CITATIONS
217	In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene. <i>Annals of Hematology</i> , 2014, 93, 1931-1933.	1.8	21
218	Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. <i>Annals of Hematology</i> , 2014, 93, 2001-2010.	1.8	58
219	How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. <i>Blood</i> , 2014, 123, 2777-2782.	1.4	130
220	Impact on Outcomes of Human Leukocyte Antigen Matching by Allele-Level Typing in Adults with Acute Myeloid Leukemia Undergoing Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 106-110.	2.0	48
221	Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 305-318.	0.4	30
222	A Prognostic Index for Patients with Refractory or in First Relapsed Acute Myeloid Leukemia Treated with FLAG-Ida or Flago-Ida. <i>Blood</i> , 2014, 124, 1049-1049.	1.4	1
223	Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults. <i>Blood</i> , 2014, 124, 2237-2237.	1.4	1
224	Haplotransplants Versus Other Alternative Donors for Allogeneic Stem Cell Transplantation in Non Hodgkin Lymphoma (NHL): A Retrospective Analysis of the EBMT Lymphoma Working Party. <i>Blood</i> , 2014, 124, 2573-2573.	1.4	1
225	Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses. <i>Blood</i> , 2014, 124, 3751-3751.	1.4	1
226	RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT. <i>Blood</i> , 2014, 124, 545-545.	1.4	2
227	The Interaction Between Collagen-Activated Platelets and Erythrocytes Selectively Increases the Release of Subsets of Platelet α -Granules Containing Pro-Angiogenic Substances. <i>Blood</i> , 2014, 124, 4171-4171.	1.4	0
228	Novel Assay for Ex Vivo Evaluation of Antiproliferative Effect of Hypomethylating Agents 5-Azacytidine and Decitabine in AML Patient Samples. <i>Blood</i> , 2014, 124, 5311-5311.	1.4	0
229	Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy. <i>Blood</i> , 2014, 124, 5223-5223.	1.4	0
230	Impact on outcomes of human leukocyte antigen matching by allele-level typing in adults with acute myeloid leukemia undergoing umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 106-10.	2.0	13
231	Novel Real-Time Polymerase Chain Reaction Assay for Simultaneous Detection of Recurrent Fusion Genes in Acute Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 678-686.	2.8	8
232	Myeloablative Cord Blood Transplantation in Adults with Acute Leukemia: Comparison of Two Different Transplant Platforms. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1725-1730.	2.0	31
233	Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 69-74.	2.0	60
234	Acute Promyelocytic Leukemia: Do We Have a New Front-Line Standard of Treatment?. <i>Current Oncology Reports</i> , 2013, 15, 445-449.	4.0	10

#	ARTICLE	IF	CITATIONS
235	Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study). Medical Mycology, 2013, 51, 150-154.	0.7	20
236	Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1387-1392.	2.0	24
237	Results of a preoperative autologous blood donation program for patients undergoing elective major spine surgery. Transfusion and Apheresis Science, 2013, 49, 345-348.	1.0	17
238	Impact of Myeloablative and Reduced Intensity Conditioning on Outcomes After Unrelated Cord Blood Transplantation for Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2013, 19, S127.	2.0	4
239	Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients. Leukemia Research, 2013, 37, 1690-1696.	0.8	36
240	WT1 isoform expression pattern in acute myeloid leukemia. Leukemia Research, 2013, 37, 1744-1749.	0.8	11
241	Phosphorylation of eIF2 β is responsible for the failure of the picornavirus internal ribosome entry site to direct translation from Sindbis virus replicons. Journal of General Virology, 2013, 94, 796-806.	2.9	11
242	Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome. Annals of Hematology, 2013, 93, 1421-2.	1.8	37
243	Screening for IDH mutations in chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2013, 54, 406-407.	1.3	4
244	Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria. Internal Medicine Journal, 2013, 43, 298-307.	0.8	29
245	Biology and management of therapy-related acute promyelocytic leukemia. Current Opinion in Oncology, 2013, 25, 695-700.	2.4	15
246	Requirements for eIF4A and eIF2 during translation of Sindbis virus subgenomic mRNA in vertebrate and invertebrate host cells. Cellular Microbiology, 2013, 15, 823-840.	2.1	29
247	The role of SWRO Barcelona-Llobregat Plant in the water supply system of Barcelona Area. Desalination and Water Treatment, 2013, 51, 111-123.	1.0	11
248	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood, 2013, 121, 1935-1943.	1.4	96
249	Arsenic Trioxide-Based Therapy Of Relapsed Acute Promyelocytic Leukemia: Updated Results Of The European Registry Of Relapsed APL (PROMYSE). Blood, 2013, 122, 1406-1406.	1.4	2
250	Intensive (2+5) Or Semi-Intensive (FLUGA) Chemotherapy For Patients With Acute Myeloid Leukemia Who Are 70 Years Of Age Or Older. Blood, 2013, 122, 2687-2687.	1.4	2
251	Treatment With Leukapheresis In Patients Diagnosed With Hyperleukocytic Acute Myeloid Leukemia. Blood, 2013, 122, 5046-5046.	1.4	2
252	Outcome Of Patients With Abnl(17p) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 303-303.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Pharmacological Profile Of Cytarabine and Idarubicin In Patient Samples (ex vivo) With Newly Diagnosed Acute Myeloid Leukemia Identifies Responders Vs Non Responders. Blood, 2013, 122, 3923-3923.	1.4	0
254	Personalizing Therapies With Ex Vivo Pharmacological Responses May Uncover The Differences Between IDA-DNR-MIT Among European AML Protocols. Blood, 2013, 122, 1294-1294.	1.4	0
255	Long-Term Outcome Of 151 Patients With Relapsed APL Receiving Second-Line With Chemotherapy Or Arsenic Trioxide-Based Regimens. Blood, 2013, 122, 3922-3922.	1.4	0
256	Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. Blood, 2013, 122, 2586-2586.	1.4	0
257	Population Pharmacological Profiles Of AML Treatments In Patient Samples By Automated Flow Cytometry; A Bridge To Individualized Medicine. Blood, 2013, 122, 1347-1347.	1.4	0
258	OUTCOME OF ANTIFUNGAL COMBINATION THERAPY FOR INVASIVE MOLD INFECTIONS IN HEMATOLOGICAL PATIENTS IS INDEPENDENT OF THE CHOSEN COMBINATION. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012011.	1.3	18
259	Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepea, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplantation, 2012, 47, 1287-1293.	2.4	124
260	Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group. Journal of Clinical Oncology, 2012, 30, 1641-1646.	1.6	49
261	A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. Current Medical Research and Opinion, 2012, 28, 789-796.	1.9	9
262	The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL). Hematology, 2012, 17, s36-s38.	1.5	5
263	Bone Marrow-Derived Cells from Male Donors Do Not Contribute to the Endometrial Side Population of the Recipient. PLoS ONE, 2012, 7, e30260.	2.5	85
264	Rapid Screening of ASXL1, IDH1, IDH2, and c-CBL Mutations in de Novo Acute Myeloid Leukemia by High-Resolution Melting. Journal of Molecular Diagnostics, 2012, 14, 594-601.	2.8	12
265	Significance of Increased Blastic-Appearing Cells in Bone Marrow Following Myeloablative Unrelated Cord Blood Transplantation in Adult Patients. Biology of Blood and Marrow Transplantation, 2012, 18, 388-395.	2.0	7
266	Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain. BMC Infectious Diseases, 2012, 12, 83.	2.9	17
267	Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia, 2012, 26, 1211-1217.	7.2	126
268	Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients. Annals of Hematology, 2012, 91, 1845-1853.	1.8	8
269	Analysis of mutational status, SNP rs16754, and expression levels of Wilms tumor 1 (WT1) gene in acute promyelocytic leukemia. Annals of Hematology, 2012, 91, 1855-1860.	1.8	17
270	Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML). Leukemia Research, 2012, 36, e50-e51.	0.8	0

#	ARTICLE	IF	CITATIONS
271	A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 410-417.	4.1	24
272	Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia. <i>Annals of Hematology</i> , 2012, 91, 1-7.	1.8	13
273	Prognostic value of cytogenetics in adult patients with Philadelphia-negative acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2012, 91, 19-25.	1.8	5
274	Translation Directed by Hepatitis A Virus IRES in the Absence of Active eIF4F Complex and eIF2. <i>PLoS ONE</i> , 2012, 7, e52065.	2.5	23
275	Aberrant Expression of the MLL5, BAALC, ID1, and WT1 Genes Is Associated with Higher Induction Mortality and Poorer Overall Survival in Acute Promyelocytic Leukemia Patients Treated with ATRA and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. <i>Blood</i> , 2012, 120, 1407-1407.	1.4	0
276	Impact of Myeloablative and Reduced Intensity Conditioning On Outcomes After Unrelated Cord Blood Transplantation for Adults with Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2012, 120, 3117-3117.	1.4	0
277	Prognostic Value of Complex Karyotype and Monosomal Karyotype in Patients with Adult Acute Lymphoblastic Leukemia Treated with Risk-Adapted Protocols. <i>Blood</i> , 2012, 120, 4785-4785.	1.4	0
278	Initial Results of the Phase I/II Panobidara Study of Panobinostat in Combination with Idarubicin and Cytarabine in Patients Aged 65 Years or Older with Newly Diagnosed Acute Myeloblastic Leukaemia (AML). <i>Blood</i> , 2012, 120, 1512-1512.	1.4	0
279	Treatment of multiple myeloma in the elderly: realities and hopes. <i>Leukemia and Lymphoma</i> , 2011, 52, 9-14.	1.3	3
280	Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). <i>Value in Health</i> , 2011, 14, 90-96.	0.3	27
281	Update on bacteraemia in oncology and hematology. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2011, 29, 48-53.	0.5	2
282	Translation of Viral mRNA without Active eIF2: The Case of Picornaviruses. <i>PLoS ONE</i> , 2011, 6, e22230.	2.5	24
283	Translation without eIF2 Promoted by Poliovirus 2A Protease. <i>PLoS ONE</i> , 2011, 6, e25699.	2.5	26
284	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. <i>Haematologica</i> , 2011, 96, 1470-1477.	3.5	59
285	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. <i>Blood</i> , 2011, 117, 1799-1805.	1.4	112
286	A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia. <i>Blood</i> , 2011, 117, 242-245.	1.4	65
287	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. <i>Blood</i> , 2011, 117, 3294-3301.	1.4	353
288	Central nervous system involvement at first relapse in patients with acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 1375-1379.	3.5	28

#	ARTICLE	IF	CITATIONS
289	Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis. <i>Haematologica</i> , 2011, 96, 621-625.	3.5	23
290	Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 1448-1456.	3.5	45
291	The European LeukemiaNet: achievements and perspectives. <i>Haematologica</i> , 2011, 96, 156-162.	3.5	15
292	CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. <i>Haematologica</i> , 2011, 96, 1557-1559.	3.5	31
293	Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. <i>Leukemia</i> , 2011, 25, 110-120.	7.2	113
294	Whole-Genome Sequencing and Acute Promyelocytic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 610.	7.4	2
295	Correction of systematic set-up error in breast and head and neck irradiation through a no-action level (NAL) protocol. <i>Clinical and Translational Oncology</i> , 2011, 13, 34-42.	2.4	16
296	Effect of storage conditions on sensory properties of Bierzo roasted pepper. <i>Journal of the Science of Food and Agriculture</i> , 2011, 91, 80-84.	3.5	4
297	Effect of cultivar and roasting technique on sensory quality of Bierzo roasted pepper. <i>Journal of the Science of Food and Agriculture</i> , 2011, 91, 2426-2430.	3.5	6
298	Aberrant methylation of tumor suppressor genes in patients with refractory anemia with ring sideroblasts. <i>Leukemia Research</i> , 2011, 35, 479-483.	0.8	9
299	Modern Approaches to Treating Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 495-503.	1.6	203
300	Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim. <i>Hematology</i> , 2011, 16, 274-277.	1.5	20
301	THE DIFFERENTIATION SYNDROME IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: EXPERIENCE OF THE PETHEMA GROUP AND REVIEW OF THE LITERATURE.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011059.	1.3	77
302	Gene Microdeletions in Adult and Pediatric Acute Lymphoblastic Leukemia,. <i>Blood</i> , 2011, 118, 3539-3539.	1.4	2
303	The Presence of An Internal Tandem Duplicate of FLT3 Receptor (ITD) Is An Unfavorable Prognostic Factor on the Outcome of Adult Patients with Acute Myeloid Leukemia (AML) Autografted in First Remission (CR1) Only in the Absence of An NPM1 Mutation,. <i>Blood</i> , 2011, 118, 4139-4139.	1.4	0
304	Outcome of Second Allogeneic SCT Following Relapse of Hematological Malignancies After a First Allogeneic SCT. <i>Blood</i> , 2011, 118, 3056-3056.	1.4	0
305	Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience,. <i>Blood</i> , 2011, 118, 3552-3552.	1.4	0
306	^{125}I -Np73/TAp73 Expression Ratio Is Associated with Poor Outcome in Acute Promyelocytic Leukemia,. <i>Blood</i> , 2011, 118, 3536-3536.	1.4	0

#	ARTICLE	IF	CITATIONS
307	Comparison of Short-Term Outcomes Between CSTIBES02 and ALL Ph08 Trials for Young Patients with Philadelphia Chromosome-Positive ALL (Ph+ALL) Differing In Imatinib Dose and Amount of Chemotherapy Before Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 2582-2582.	1.4	0
308	Quantitative Expression Analysis of WT1 Main Isoforms in AML. <i>Blood</i> , 2011, 118, 1469-1469.	1.4	0
309	Intravenous Busulfan (IV Bu)-Based Conditioning Regimen Before Allogeneic Stem Cell Transplantation (allo-SCT) for Adults with Acute Lymphoid Leukemia (ALL): A Survey From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2011, 118, 3005-3005.	1.4	1
310	Analysis of ASXL1, IDH1, IDH2, c-CBL, and WT1 Mutations in De Novo Acute Myeloid Leukaemia. <i>Blood</i> , 2011, 118, 1450-1450.	1.4	0
311	Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. <i>Blood</i> , 2010, 115, 1690-1696.	1.4	232
312	Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. <i>Blood</i> , 2010, 115, 5137-5146.	1.4	278
313	Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. <i>Blood</i> , 2010, 116, 5650-5659.	1.4	33
314	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Haematologica</i> , 2010, 95, 424-431.	3.5	84
315	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010, 115, 453-474.	1.4	2,963
316	High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA. <i>Medical Oncology</i> , 2010, 27, 702-707.	2.5	1
317	Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. <i>European Journal of Haematology</i> , 2010, 85, 363-365.	2.2	34
318	Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: Association of DNA breaks with specific DNA motifs at <i>PML</i> and <i>RARA</i> loci. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 726-732.	2.8	32
319	Epigenetic regulation of the noncanonical Wnt pathway in acute myeloid leukemia. <i>Cancer Science</i> , 2010, 101, 425-432.	3.9	43
320	Influence of storage conditions on the sensory quality of a high acid apple. <i>International Journal of Food Science and Technology</i> , 2010, 45, 2352-2357.	2.7	13
321	Long-term management of chronic immune thrombocytopenic purpura in adults. <i>International Journal of General Medicine</i> , 2010, 3, 305.	1.8	9
322	Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-<i>Trans</i>-Retinoic Acid and Anthracycline-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 3872-3879.	1.6	74
323	Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2010, 45, 925-932.	2.4	24
324	Treatment of Patients With Acute Promyelocytic Leukemia: A Consensus Statement on Risk-Adapted Approaches to Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, S122-S126.	0.4	10

#	ARTICLE	IF	CITATIONS
325	Risk-Adapted Treatment for Low- and Intermediate-Risk Acute Promyelocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S130-S134.	0.4	5
326	Translation Driven by Picornavirus IRES Is Hampered from Sindbis Virus Replicons: Rescue by Poliovirus 2A Protease. Journal of Molecular Biology, 2010, 402, 101-117.	4.2	21
327	Cord Blood Transplantation from Unrelated Donors in Adults with High-Risk Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2010, 16, 86-94.	2.0	79
328	Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source. Biology of Blood and Marrow Transplantation, 2010, 16, 957-966.	2.0	35
329	Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2010, 16, 1589-1595.	2.0	30
330	Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study. Transfusion and Apheresis Science, 2010, 43, 299-303.	1.0	56
331	International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010, 115, 168-186.	1.4	1,802
332	Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thrombosis Research, 2010, 125, S51-S54.	1.7	67
333	A new reliable fluorescence in situ hybridization method for identifying multiple specific cytogenetic abnormalities in acute myeloid leukemia. Leukemia and Lymphoma, 2010, 51, 680-685.	1.3	3
334	CD34+ Cell Dose Is the Major Cell Dose Determinant of Myeloid Engraftment After Single Umbilical Cord Blood Transplantation (sUCBT) for Adult Patients with High-Risk Hematologic Malignancies. Blood, 2010, 116, 1339-1339.	1.4	1
335	Treatment of Molecular and Clinical Relapse of Acute Promyelocytic Leukemia (APL) with Arsenic Trioxide: Results of the European Registry of Relapsed APL. Blood, 2010, 116, 15-15.	1.4	7
336	Outcomes in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation Using Intravenous Busulfan and Melphalan: A Matched Comparison to a Double Autologous Transplant Strategy. Blood, 2010, 116, 3560-3560.	1.4	1
337	Outcome of APL in Young Children and Adolescents in Two Consecutive Trials of the European APL Group. Blood, 2010, 116, 507-507.	1.4	3
338	DNA Methylation Profiles and Their Relationship with Cytogenetic Status in Adult Acute Myeloid Leukemia. PLoS ONE, 2010, 5, e12197.	2.5	73
339	Specific Chemotherapy and Rituximab in HIV-Infected Patients with Burkitt's Leukemia or Lymphoma. Results of a German-Spanish Study and Analysis of Prognostic Factors. Blood, 2010, 116, 3944-3944.	1.4	10
340	Assessment of Safety and Efficacy of a New Intravenous Immunoglobulin (IGIV3I 10% Grifols) in Subjects with Chronic Immune Thrombocytopenia. Blood, 2010, 116, 4669-4669.	1.4	0
341	Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies. Haematologica, 2009, 94, 827-832.	3.5	29
342	Dual Mechanism for the Translation of Subgenomic mRNA from Sindbis Virus in Infected and Uninfected Cells. PLoS ONE, 2009, 4, e4772.	2.5	44

#	ARTICLE	IF	CITATIONS
343	Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia. <i>Advances in Hematology</i> , 2009, 2009, 1-4.	1.0	16
344	Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience. <i>Journal of Clinical Oncology</i> , 2009, 27, 2668-2676.	1.6	90
345	Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1303-1310.	3.0	57
346	Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. <i>Leukemia</i> , 2009, 23, 1658-1666.	7.2	120
347	Absence of mutations in the tyrosine kinase and juxtamembrane domains of C-FMS gene in chronic myelomonocytic leukemia (CMML). <i>Leukemia Research</i> , 2009, 33, e162-e163.	0.8	3
348	Imipenem/Cilastatin with or without Glycopeptide as Initial Antibiotic Therapy for Recipients of Autologous Stem Cell Transplantation: Results of a Spanish Multicenter Study. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 512-516.	2.0	7
349	Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 730-740.	2.0	54
350	Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. <i>Leukemia and Lymphoma</i> , 2009, 50, 216-222.	1.3	24
351	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. <i>Blood</i> , 2009, 113, 2386-2393.	1.4	2,128
352	Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2009, 113, 1875-1891.	1.4	856
353	Rapid Detection of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia Using High-Resolution Melting Analysis. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 458-463.	2.8	24
354	FLT3 inhibition as a targeted therapy for acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2009, 21, 594-600.	2.4	46
355	Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. <i>Haematologica</i> , 2009, 94, 1242-1249.	3.5	93
356	Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. <i>Blood</i> , 2009, 113, 775-783.	1.4	279
357	Activity and Safety of Lenalidomide and Dexamethasone in Multiple Myeloma Patients with Advanced Renal Failure: a Spanish Multicenter Retrospective Study.. <i>Blood</i> , 2009, 114, 1886-1886.	1.4	5
358	Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial Including the Use of Propensity Score (PS) Method to Reduce Assignment Bias.. <i>Blood</i> , 2009, 114, 322-322.	1.4	5
359	Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group.. <i>Blood</i> , 2009, 114, 6-6.	1.4	11
360	Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.. <i>Blood</i> , 2009, 114, 788-788.	1.4	17

#	ARTICLE	IF	CITATIONS
361	Salvage Therapy with Chemotherapy- or Arsenic Trioxide-Based Regimens for Acute Promyelocytic Leukemia in First Relapse.. Blood, 2009, 114, 1062-1062.	1.4	1
362	A Methylation Profile of Tumor Suppressor Genes Predicts a Poorer Survival in Patients with Refractory Anemia with Ringed Sideroblasts.. Blood, 2009, 114, 2780-2780.	1.4	0
363	Epigenomic Analysis of Acute Myeloid Leukemia Identifies Specific Patterns and Markers with Clinical and Biological Relevance.. Blood, 2009, 114, 2394-2394.	1.4	0
364	One Year Reinductions with Vincristine, Asparaginase and Prednisone as Post-Remission Therapy Improves Outcome in Children with Intermediate Risk (IR) Acute Lymphoblastic Leukemia (ALL).. Blood, 2009, 114, 2026-2026.	1.4	0
365	A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia (APL) Patients (PTS) Who Have Received Prior Therapy with All-Trans Retinoic Acid and Arsenic Trioxide (STAR-1 trial).. Blood, 2009, 114, 2050-2050.	1.4	0
366	Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA Groups.. Blood, 2009, 114, 845-845.	1.4	1
367	Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim in Two Phase 3 Placebo-Controlled Clinical Trials.. Blood, 2009, 114, 891-891.	1.4	19
368	Chronic lymphocytic leukaemia: prognostic value of lymphocyte morphological subtypes. A multivariate survival analysis in 146 patients. British Journal of Haematology, 2008, 77, 478-485.	2.5	60
369	Acute Promyelocytic Leukemia: Recent Advances in Diagnosis and Management. Seminars in Oncology, 2008, 35, 401-409.	2.2	68
370	Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): Comparison with WT1 gene expression. Clinica Chimica Acta, 2008, 395, 120-123.	1.1	32
371	Update on pulmonary infections in patients with hematologic malignancies and hematopoietic stem cell recipients. Enfermedades Infecciosas Y Microbiología Clínica, 2008, 26, 58-71.	0.5	0
372	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet, The, 2008, 371, 395-403.	13.7	784
373	Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica, 2008, 93, 67-74.	3.5	188
374	Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96. Journal of Clinical Oncology, 2008, 26, 1843-1849.	1.6	239
375	Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood, 2008, 111, 1078-1084.	1.4	156
376	Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood, 2008, 111, 3395-3402.	1.4	303
377	Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood, 2008, 112, 3383-3390.	1.4	74
378	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood, 2008, 112, 3130-3134.	1.4	154

#	ARTICLE	IF	CITATIONS
379	Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q-syndrome. <i>Blood</i> , 2008, 112, 918-918.	1.4	78
380	Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. <i>Haematologica</i> , 2008, 93, 921-924.	3.5	100
381	Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. <i>Haematologica</i> , 2008, 93, 735-740.	3.5	62
382	Risk-Adapted Treatment of Acute Promyelocytic Leukemia: Results of the PETHEMA LPA2005 Trial Using All-Trans Retinoic Acid and Anthracycline with Cytarabine for High-Risk Patients. <i>Blood</i> , 2008, 112, 138-138.	1.4	1
383	Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL. <i>Blood</i> , 2008, 112, 139-139.	1.4	2
384	Incidence, Outcome and Risk Factors of Pseudotumor Cerebri after All- Trans Retinoic Acid and Anthracycline-Based Chemotherapy in Patients with Acute Promyelocytic Leukemia. <i>Blood</i> , 2008, 112, 2992-2992.	1.4	5
385	Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial.. <i>Blood</i> , 2008, 112, 3291-3291.	1.4	2
386	Long-Term Safety Profile of Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP).. <i>Blood</i> , 2008, 112, 3415-3415.	1.4	5
387	Unrelated Donor Umbilical Cord Blood Transplantation (UD-UCBT) for Adult Patients with High-Risk Acute Myeloid Leukemia (AML). <i>Blood</i> , 2008, 112, 4401-4401.	1.4	10
388	Unrelated Transplants for Poor Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Comparative Analysis Based on the Hematopoietic Progenitor Source.. <i>Blood</i> , 2008, 112, 969-969.	1.4	0
389	Treatment with All-Trans Retinoic Acid and Anthracycline Monochemotherapy in Children with Acute Promyelocytic Leukemia: Analysis of Three Sequential Multicenter Trials of the PETHEMA Group. <i>Blood</i> , 2008, 112, 137-137.	1.4	0
390	Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome.. <i>Blood</i> , 2008, 112, 1649-1649.	1.4	0
391	Viral Translation Is Coupled to Transcription in Sindbis Virus-Infected Cells. <i>Journal of Virology</i> , 2007, 81, 7061-7068.	3.4	36
392	The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. <i>Haematologica</i> , 2007, 92, 308-314.	3.5	76
393	Bleeding and thrombosis in acute leukemia: What does the future of therapy look like?. <i>Thrombosis Research</i> , 2007, 120, S99-S106.	1.7	73
394	Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 2367-2374.	1.3	19
395	Current treatment of acute promyelocytic leukemia. <i>Haematologica</i> , 2007, 92, 289-291.	3.5	16
396	An iminophosphorane-based approach for the synthesis of spiropyrrolidine-imidazole derivatives. <i>Tetrahedron</i> , 2007, 63, 1849-1856.	1.9	13

#	ARTICLE	IF	CITATIONS
397	The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2007, 31, 947-953.	0.8	40
398	Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?. <i>Leukemia Research</i> , 2007, 31, 1315-1317.	0.8	2
399	Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2007, 39, 461-469.	2.4	55
400	Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. <i>Bone Marrow Transplantation</i> , 2007, 39, 555-561.	2.4	91
401	Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. <i>Leukemia</i> , 2007, 21, 446-452.	7.2	124
402	Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. <i>British Journal of Haematology</i> , 2007, 136, 590-596.	2.5	75
403	MLL amplification in acute myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2007, 174, 127-131.	1.0	17
404	A Study of Incidence and Characteristics of Infections in 476 Patients from a Single Center Undergoing Autologous Blood Stem Cell Transplantation. <i>International Journal of Hematology</i> , 2007, 86, 186-192.	1.6	16
405	Genetic markers for doubled haploid response in barley. <i>Euphytica</i> , 2007, 158, 287-294.	1.2	33
406	Secondary Acute Myeloid Leukemia and Myelodysplastic Syndromes Following ATRA and Anthracycline Monochemotherapy Treatment for Acute Promyelocytic Leukemia.. <i>Blood</i> , 2007, 110, 1838-1838.	1.4	1
407	The Prognostic Significance of Complex Karyotype in Philadelphia Chromosome-Negative (Ph ⁻) Acute Lymphoblastic Leukemia (ALL) in Adults Is Related with Risk Group.. <i>Blood</i> , 2007, 110, 3501-3501.	1.4	2
408	Incidence and Prognostic Factors for Infectious and Hemorrhagic Death in Patients with Acute Myeloid Leukemia: A Single-Centre Study.. <i>Blood</i> , 2007, 110, 4300-4300.	1.4	1
409	Evaluation of AMG 531 Efficacy in Nonsplenectomized Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study.. <i>Blood</i> , 2007, 110, 565-565.	1.4	5
410	Risk-Adapted Treatment of Acute Promyelocytic Leukemia: Updated Results of the Spanish PETHEMA LPA99 Trial Using ATRA and Anthracycline Monochemotherapy.. <i>Blood</i> , 2007, 110, 590-590.	1.4	1
411	Central Nervous System Relapse in Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Reinforced Anthracycline Monochemotherapy.. <i>Blood</i> , 2007, 110, 592-592.	1.4	1
412	Low Transplant-Related Mortality in Patients with Hematologic Malignancies Undergoing Umbilical Cord Blood Transplantation (UCBT) with Thiotepe (TT), Once-Daily Intravenous (IV) Busulfan (BU), Fludarabine (FLU) and Anti-Thymocyte Globulin (ATG).. <i>Blood</i> , 2007, 110, 618-618.	1.4	2
413	Toxicity and Early Response after Single Daily Dose of Intravenous Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma.. <i>Blood</i> , 2007, 110, 4928-4928.	1.4	0
414	FLAG-IDA Regimen (Fludarabine, Cytarabine, Idarubicin and G-CSF) in the Treatment of Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes.. <i>Blood</i> , 2007, 110, 2866-2866.	1.4	2

#	ARTICLE	IF	CITATIONS
415	Incidence and Characteristics of Acute Promyelocytic Leukemia in Adult Patients. A Single Centre Registry Study.. Blood, 2007, 110, 4301-4301.	1.4	0
416	Unrelated Donor Umbilical Cord Blood Transplantation (UD-UCBT) for Adult Patients with High-Risk Acute Lymphoblastic Leukemia (ALL).. Blood, 2007, 110, 2024-2024.	1.4	1
417	Prognostic Value of Immunophenotype in Patients with Non-Promyelocytic Acute Myeloid Leukemia Treated with Intensive Chemotherapy. A Single Centre Study.. Blood, 2007, 110, 2391-2391.	1.4	0
418	Arsenic Trioxide. American Journal of Cancer, 2006, 5, 183-191.	0.4	8
419	Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leukemia and Lymphoma, 2006, 47, 1488-1494.	1.3	68
420	Molecular detection of Spanish β^0 -thalassemia associated with β^0 -thalassemia identified during prenatal diagnosis. Clinica Chimica Acta, 2006, 368, 195-198.	1.1	3
421	Translation of Sindbis Virus 26S mRNA Does Not Require Intact Eukariotic Initiation Factor 4G. Journal of Molecular Biology, 2006, 355, 942-956.	4.2	45
422	Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia, 2006, 20, 35-41.	7.2	149
423	Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia, 2006, 20, 404-409.	7.2	28
424	Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials). Leukemia, 2006, 20, 905-907.	7.2	15
425	Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leukemia Research, 2006, 30, 1471-1491.	0.8	94
426	Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. European Journal of Haematology, 2006, 78, 061114074547002-???	2.2	63
427	A t(17;20)(q21;q12) masking a variant t(15;17)(q22;q21) in a patient with acute promyelocytic leukemia. Cancer Genetics and Cytogenetics, 2006, 168, 73-76.	1.0	9
428	High-level amplification of the RUNX1 gene in two cases of childhood acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2006, 170, 171-174.	1.0	9
429	Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries. Clinical Infectious Diseases, 2006, 43, e29-e38.	5.8	100
430	Treatment of Acute Promyelocytic Leukemia. Hematology American Society of Hematology Education Program, 2006, 2006, 147-155.	2.5	66
431	Incidence and Risk Factors for Thrombosis in Patients with Acute Promyelocytic Leukemia. Experience of the PETHEMA LPA96 and LPA99 Protocols.. Blood, 2006, 108, 1503-1503.	1.4	19
432	Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Classical Risk Factors and Minimal Residual Disease (MRD). Interim Results of the PETHEMA ALL-AR-03 Trial.. Blood, 2006, 108, 1872-1872.	1.4	0

#	ARTICLE	IF	CITATIONS
433	Incidence and Risk Factors for Central Nervous System Relapse in Adult Patients with Acute Myeloid Leukemia: A Single Center Experience.. Blood, 2006, 108, 4579-4579.	1.4	0
434	SHP-1 (PTPN6) Gene Supression by FLT3/ITD Defines an Aggressive Subgroup of Myeloid Malignancies.. Blood, 2006, 108, 1907-1907.	1.4	0
435	Clinico-Biological Characteristics and Prognosis of Non-M3 Acute Myeloid Leukemia with High Percentage of Myeloperoxidase Positive Blasts. Single Center Experience.. Blood, 2006, 108, 4462-4462.	1.4	0
436	Prognostic Value of Immunophenotype Analysis in Patients with Acute Promyelocytic Leukemia (APL) Treated with All-Transretinoic Acid and Anthracyclin Monochemotherapy.. Blood, 2006, 108, 2345-2345.	1.4	0
437	Rituximab Monotherapy for Cold Agglutinin Disease. Report on 16 Patients from a Single Institution.. Blood, 2006, 108, 965-965.	1.4	36
438	FLT3 Mutations in a Large Series of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy.. Blood, 2006, 108, 2348-2348.	1.4	0
439	Incidence and Risk Factors for Hemorrhagic Cystitis in Adult Patients Undergoing Allogeneic Stem-Cell Transplantation.. Blood, 2006, 108, 2964-2964.	1.4	0
440	Long-Term Outcome and Prognostic Factors after Single-Unit Umbilical Cord-Blood Transplantation (UCBT) for Adults with Hematologic Malignancies.. Blood, 2006, 108, 3129-3129.	1.4	0
441	Outcome of Patients with Primary Refractory Acute Myeloid Leukemia (AML) Undergoing Myeloablative Allogeneic Stem-Cell Transplantation (alloSCT) from HLA-Identical Sibling: Favorable Outcome in a Subset of Patients.. Blood, 2006, 108, 3022-3022.	1.4	0
442	Retinoic Acid Syndrome in Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy.. Blood, 2006, 108, 2010-2010.	1.4	0
443	Recent advances in the treatment of APL. Clinical Advances in Hematology and Oncology, 2006, 4, 727-9.	0.3	2
444	Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood, 2005, 105, 3019-3025.	1.4	116
445	Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia. Leukemia Research, 2005, 29, 595-597.	0.8	10
446	SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. British Journal of Haematology, 2005, 129, 791-794.	2.5	22
447	Transplantation of CD34+ selected peripheral blood to HLA-identical sibling patients with aplastic anaemia: results from a single institution. Bone Marrow Transplantation, 2005, 36, 325-329.	2.4	9
448	Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia, 2005, 19, 230-233.	7.2	65
449	Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia, 2005, 19, 1153-1160.	7.2	134
450	Autologous and Allogeneic Stem-Cell Transplantation As Salvage Treatment of Acute Promyelocytic Leukemia Initially Treated With All- <i>i>Trans</i>-Retinoic Acid: A Retrospective Analysis of the European Acute Promyelocytic Leukemia Group. Journal of Clinical Oncology, 2005, 23, 120-126.</i>	1.6	122

#	ARTICLE	IF	CITATIONS
451	Treatment With All- <i>Trans</i> Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 7632-7640.	1.6	126
452	Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study. <i>Current Medical Research and Opinion</i> , 2005, 21, 645-655.	1.9	17
453	Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. <i>Current Medical Research and Opinion</i> , 2005, 21, 403-411.	1.9	44
454	Practice Points, Consensus, and Controversial Issues in the Management of Patients with Newly Diagnosed Acute Promyelocytic Leukemia. <i>Oncologist</i> , 2005, 10, 806-814.	3.7	24
455	Identification of Risk Factors for Tumour Lysis Syndrome in Patients with Acute Myeloid Leukaemia: Development of a Prognostic Score.. <i>Blood</i> , 2005, 106, 1843-1843.	1.4	29
456	Long-Term Follow up of Healthy Donors Receiving G-CSF for Peripheral Blood Progenitor Cell Mobilization and Collection.. <i>Blood</i> , 2005, 106, 1975-1975.	1.4	2
457	Prophylaxis of Cytomegalovirus (CMV) Infection and Disease after Unrelated-Donor Umbilical Cord-Blood Transplantation (UCBT) with Intravenous Ganciclovir or Oral Valganciclovir.. <i>Blood</i> , 2005, 106, 5460-5460.	1.4	0
458	Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia. <i>Haematologica</i> , 2005, 90, 840-5.	3.5	10
459	Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. <i>Haematologica</i> , 2005, 90, 1231-5.	3.5	51
460	Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. <i>Haematologica</i> , 2005, 90, 1346-56.	3.5	129
461	Unrelated-Donor Cord Blood Transplantation for Adult Hematological Malignancies. <i>Leukemia and Lymphoma</i> , 2004, 45, 11-18.	1.3	13
462	Cord-Blood Transplantation in Patients with Leukemia – A Real Alternative for Adults. <i>New England Journal of Medicine</i> , 2004, 351, 2328-2330.	27.0	47
463	Quantitative Assessment of PML-RAR α and BCR-ABL by Two Real-Time PCR Instruments: Multiinstitutional Laboratory Trial. <i>Clinical Chemistry</i> , 2004, 50, 1088-1092.	3.2	8
464	Outcome of Childhood Acute Promyelocytic Leukemia With All- <i>Trans</i> -Retinoic Acid and Chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 1404-1412.	1.6	131
465	Peripheral Blood Stem Cell Collection after Intermediate-Dose Cytarabine in Adult Patients with Acute Myeloblastic Leukemia Undergoing Autologous Blood Stem Cell Transplantation in First Complete Remission. <i>International Journal of Hematology</i> , 2004, 80, 168-173.	1.6	1
466	Immunofluorescent analysis with the anti-PML monoclonal antibody PG-M3 for rapid and accurate genetic diagnosis of acute promyelocytic leukemia. <i>Annals of Hematology</i> , 2004, 83, 687-690.	1.8	21
467	Locked Nucleic Acid-Enhanced Detection of 1100delC*CHEK2 Germ-Line Mutation in Spanish Patients with Hematologic Malignancies. <i>Clinical Chemistry</i> , 2004, 50, 2201-2204.	3.2	7
468	Membrane-permeabilizing motif in Semliki forest virus E1 glycoprotein. <i>FEBS Letters</i> , 2004, 576, 417-422.	2.8	10

#	ARTICLE	IF	CITATIONS
469	All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. <i>Blood</i> , 2004, 104, 3490-3493.	1.4	98
470	Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols.. <i>Blood</i> , 2004, 104, 2019-2019.	1.4	5
471	Outcome and Prognostic Factors after Unrelated Donor Umbilical Cord Blood Transplantation in Adult Patients with Hematologic Malignancies Transplanted in Early Disease Stages.. <i>Blood</i> , 2004, 104, 2149-2149.	1.4	12
472	Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the ATRA Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99.. <i>Blood</i> , 2004, 104, 394-394.	1.4	5
473	Causes of Induction Failure in Newly Diagnosed Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Idarubicin (AIDA).. <i>Blood</i> , 2004, 104, 887-887.	1.4	1
474	Real-Time Quantification of the AML Rearrangements, AML1-ETO and TEL-AML1, in Acute Leukemia. , 2004, , 141-155.		0
475	PML/RAR α Mediates Resistance to Apoptosis and Down-Regulation of the NF- κ B Pathway in Acute Promyelocytic Leukemia.. <i>Blood</i> , 2004, 104, 4283-4283.	1.4	0
476	Comparison of Intensive Chemotherapy (CHT), Allogeneic (ALLO) or Autologous (AUTO) Stem Cell Transplantation (SCT) as Post-Remission Treatment for Adult Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL). Final Results of the PETHEMA ALL-93 Trial.. <i>Blood</i> , 2004, 104, 2731-2731.	1.4	0
477	Patterns of Expression of SHP-1 and JAK-2p in Myelodysplastic Syndromes: A Potential New Prognostic Factor.. <i>Blood</i> , 2004, 104, 3430-3430.	1.4	0
478	Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. <i>Haematologica</i> , 2004, 89, 926-33.	3.5	97
479	Basal CD34(+) cell count predicts peripheral blood progenitor cell mobilization and collection in healthy donors after administration of granulocyte colony-stimulating factor. <i>Haematologica</i> , 2004, 89, 1530-2.	3.5	11
480	Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia? a randomized, placebo-controlled, double-blind safety and efficacy study. <i>Annals of Hematology</i> , 2003, 82, 677-683.	1.8	25
481	Positive selection for CD34 + reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. <i>Experimental Hematology</i> , 2003, 31, 545-550.	0.4	31
482	De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19. <i>Genes Chromosomes and Cancer</i> , 2003, 36, 406-412.	2.8	27
483	Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer. <i>Cancer</i> , 2003, 98, 1048-1054.	4.1	130
484	Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies. <i>Leukemia Research</i> , 2003, 27, 5-12.	0.8	40
485	Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. <i>Leukemia</i> , 2003, 17, 339-342.	7.2	71
486	Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. <i>Leukemia</i> , 2003, 17, 1600-1604.	7.2	70

#	ARTICLE	IF	CITATIONS
487	Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemia. Best Practice and Research in Clinical Haematology, 2003, 16, 433-451.	1.7	28
488	Adding arabinosylcytosine to idarubicin induction therapy may not improve survival for people with newly diagnosed acute promyelocytic leukaemia, , Abstracted from: Avvisati G, Petti M, Lo-Coco F et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study. LAP 0389 with 7 years of minimal follow-up. Blood 2002; 100 (9): 3141-6.. Cancer Treatment Reviews, 2003, 29, 143-146.	7.7	1
489	Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2003, 21, 4642-4649.	1.6	2,425
490	Therapy-Related Acute Promyelocytic Leukemia. Journal of Clinical Oncology, 2003, 21, 2123-2137.	1.6	212
491	Interfacial Domains in Sindbis Virus 6K Protein. Journal of Biological Chemistry, 2003, 278, 2051-2057.	3.4	53
492	Post-transplant Burkitt's Leukemia or Lymphoma. Study of Five Cases Treated with Specific Intensive Therapy (PETHEMA ALL-3/97 Trial). Leukemia and Lymphoma, 2003, 44, 1541-1543.	1.3	23
493	Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monotherapy: a multicenter study by the PETHEMA group. Blood, 2003, 103, 1237-1243.	1.4	395
494	Post-transplant Burkitt's Leukemia or Lymphoma. Study of Five Cases Treated with Specific Intensive Therapy (PETHEMA ALL-3/97 Trial). Leukemia and Lymphoma, 2003, 44, 1541-1543.	1.3	6
495	Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica, 2003, 88, 19-24.	3.5	135
496	Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation. Haematologica, 2003, 88, 300-5.	3.5	20
497	Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica, 2003, 88, 445-53.	3.5	32
498	Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation. Haematologica, 2003, 88, 919-22.	3.5	25
499	Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica, 2003, 88, 1213-20.	3.5	29
500	Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood, 2002, 100, 724-727.	1.4	68
501	Second Mobilization and Collection of Peripheral Blood Progenitor Cells in Healthy Donors Is Associated with Lower CD34+Cell Yields. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 705-709.	1.8	16
502	The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Human Molecular Genetics, 2002, 11, 1391-1397.	2.9	139
503	CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic Transplantation. Bone Marrow Transplantation, 2002, 29, 205-211.	2.4	11
504	Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies. Bone Marrow Transplantation, 2002, 29, 825-832.	2.4	33

#	ARTICLE	IF	CITATIONS
505	Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 79-88.	3.0	58
506	Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. <i>Transfusion</i> , 2002, 42, 4-9.	1.6	87
507	Platelet transfusion and thrombotic thrombocytopenic purpura. <i>Transfusion</i> , 2002, 42, 1384-1385.	1.6	19
508	Rapid detection of the major Mediterranean β -thalassaemia mutations by real-time polymerase chain reaction using fluorophore-labelled hybridization probes. <i>British Journal of Haematology</i> , 2002, 119, 554-557.	2.5	21
509	Infectious complications in patients undergoing unrelated donor bone marrow transplantation: experience from a single institution. <i>Clinical Microbiology and Infection</i> , 2002, 8, 725-733.	6.0	29
510	Identification of two atypical PML-RAR transcripts in two patients with acute promyelocytic leukemia. <i>Leukemia Research</i> , 2002, 26, 439-442.	0.8	18
511	FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. <i>Leukemia Research</i> , 2002, 26, 725-730.	0.8	41
512	Early infections in adult patients undergoing unrelated donor cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 937-943.	2.4	97
513	Unrelated donor umbilical cord blood transplantation in adults. <i>Leukemia</i> , 2002, 16, 1984-1991.	7.2	46
514	Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes. <i>Haematologica</i> , 2002, 87, 23-32.	3.5	9
515	Recurrent bacteremia caused by <i>Rhodococcus equi</i> in a non-neutropenic patient with acute myeloid leukemia in complete remission. <i>Haematologica</i> , 2002, 87, ECR03.	3.5	4
516	Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. <i>Haematologica</i> , 2002, 87, 154-66.	3.5	37
517	The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings. <i>Blood</i> , 2001, 97, 383-387.	1.4	118
518	Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. <i>Blood</i> , 2001, 98, 2332-2338.	1.4	220
519	Classifying Chronic Myelomonocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2001, 19, 3790-3792.	1.6	3
520	Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. <i>British Journal of Haematology</i> , 2001, 114, 174-176.	2.5	135
521	Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the $PML-RAR$ isoforms: a study of the PETHEMA group. <i>British Journal of Haematology</i> , 2001, 114, 99-103.	2.5	52
522	Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2001, 114, 721-723.	2.5	67

#	ARTICLE	IF	CITATIONS
523	Absence of platelet response after eradication of <i>Helicobacter pylori</i> infection in patients with chronic idiopathic thrombocytopenic purpura. British Journal of Haematology, 2001, 115, 1002-1003.	2.5	129
524	Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor?. Transfusion, 2001, 41, 106-110.	1.6	37
525	Donor age-related differences in PBPC mobilization with rHuG-CSF. Transfusion, 2001, 41, 201-205.	1.6	50
526	A convergent approach to midpacamide and dispacamide pyrrole-imidazole marine alkaloids. Tetrahedron Letters, 2001, 42, 851-854.	1.4	45
527	Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2001, 27, 21-25.	2.4	23
528	Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplantation, 2001, 27, 405-412.	2.4	70
529	Uncertain role of increased intensity chemotherapy with high-dose cytarabine in acute promyelocytic leukemia. Leukemia, 2001, 15, 1999-1999.	7.2	2
530	Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. Leukemia Research, 2001, 25, 685-692.	0.8	12
531	Association between Antifungal Prophylaxis and Rate of Documented Bacteremia in Febrile Neutropenic Cancer Patients. Clinical Infectious Diseases, 2001, 32, 1532-1537.	5.8	31
532	Sindbis Virus Variant with a Deletion in the 6K Gene Shows Defects in Glycoprotein Processing and Trafficking: Lack of Complementation by a Wild-Type 6K Gene in trans. Journal of Virology, 2001, 75, 7778-7784.	3.4	48
533	Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution. Bone Marrow Transplantation, 2001, 27, 693-701.	2.4	37
534	Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34+ positive selection. Bone Marrow Transplantation, 2001, 27, 983-988.	2.4	28
535	Quantitative Detection of AML1-ETO Rearrangement by Real-Time RT-PCR Using Fluorescently Labeled Probes. Leukemia and Lymphoma, 2001, 42, 747-756.	1.3	18
536	All-Trans Retinoic ACID and Low-Dose Chemotherapy For Acute Promyelocytic Leukaemia. British Journal of Haematology, 2000, 109, 896-897.	2.5	6
537	Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. Leukemia, 2000, 14, 1371-1377.	7.2	157
538	Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis. Bone Marrow Transplantation, 2000, 25, 1115-1119.	2.4	47
539	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. British Journal of Haematology, 2000, 111, 801-806.	2.5	18
540	Problematic WHO Reclassification of Myelodysplastic Syndromes. Journal of Clinical Oncology, 2000, 18, 3447-3452.	1.6	72

#	ARTICLE	IF	CITATIONS
541	Graft-versus-tumour effect in non-small-cell lung cancer after allogeneic peripheral blood stem cell transplantation. SHORT REPORT. British Journal of Haematology, 2000, 111, 708-710.	2.5	29
542	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. British Journal of Haematology, 2000, 111, 801-806.	2.5	127
543	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. Blood, 1999, 94, 1192-1200.	1.4	682
544	Use of Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) for Carcinoembryonic Antigen, Cytokeratin 19, and Maspin in the Detection of Tumor Cells in Leukapheresis Products from Patients with Breast Cancer: Comparison with Immunocytochemistry. Stem Cells and Development, 1999, 8, 53-61.	1.0	34
545	Response to Plasma Exchange and Steroids as Combined Therapy for Patients with Thrombotic Thrombocytopenic Purpura. Acta Haematologica, 1999, 102, 12-16.	1.4	16
546	Carboplatin plus cytarabine in the treatment of high-risk acute myeloblastic leukemia. Leukemia, 1999, 13, 161-165.	7.2	6
547	Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry. Bone Marrow Transplantation, 1999, 24, 723-728.	2.4	49
548	Liver disease as primary manifestation of multiple myeloma in a young man. Leukemia Research, 1999, 23, 403-405.	0.8	14
549	Autologous peripheral blood stem cell transplantation for acute leukaemias. Best Practice and Research in Clinical Haematology, 1999, 12, 139-150.	1.7	7
550	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. Blood, 1999, 94, 1192-1200.	1.4	10
551	A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia. Blood, 1999, 94, 3694-3701.	1.4	1
552	Prolonged molecular remission after PML/RAR α -positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft?. Leukemia, 1998, 12, 992-995.	7.2	24
553	Preliminary experience in external quality control of RT-PCR PML-RAR α detection in promyelocytic leukemia. Leukemia, 1998, 12, 2024-2028.	7.2	26
554	Comparison of Two Reverse Transcription-Polymerase Chain Reaction Methods for Detection of AML1/ETO Rearrangement in the M2 Subtype of Acute Myeloid Leukaemia. Clinical Chemistry and Laboratory Medicine, 1998, 36, 137-42.	2.3	1
555	All-trans-Retinoic Acid in Acute Promyelocytic Leukemia. New England Journal of Medicine, 1998, 338, 393-394.	27.0	19
556	Deep Infections Caused by <i>Scedosporium prolificans</i> : A Report on 16 Cases in Spain and a Review of the Literature. Medicine (United States), 1997, 76, 256-265.	1.0	196
557	International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. Blood, 1997, 89, 2079-2088.	1.4	4,078
558	A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia. Blood, 1997, 90, 4710-4718.	1.4	306

#	ARTICLE	IF	CITATIONS
559	Etiopathogeny, prognosis and therapy of myelodysplastic syndromes. Hematology and Cell Therapy, 1997, 39, 277-294.	0.7	14
560	A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia. Blood, 1997, 90, 4710-4718.	1.4	9
561	Myelodysplastic syndromes. Critical Reviews in Oncology/Hematology, 1996, 23, 57-93.	4.4	15
562	Disseminated Blastoschizomyces capitatus infection in acute myeloblastic leukaemia. Supportive Care in Cancer, 1996, 4, 291-293.	2.2	19
563	3 Immunophenotyping of AML and MDS and detection of residual disease. Best Practice and Research: Clinical Haematology, 1996, 9, 35-55.	1.1	11
564	BONE MARROW ASSESSMENT IN B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA: ASPIRATE OR BIOPSY?. British Journal of Haematology, 1996, 95, 754-755.	2.5	5
565	Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) by All Transretinoic Acid (ATRA) Combined with Chemotherapy: The European Experience. Leukemia and Lymphoma, 1995, 16, 431-437.	1.3	28
566	A Role for 3AB Protein in Poliovirus Genome Replication. Journal of Biological Chemistry, 1995, 270, 14430-14438.	3.4	46
567	On the fractional integral of Weyl in L p. Mathematische Zeitschrift, 1994, 215, 209-221.	0.9	2
568	Acute Myeloblasts Leukemia with Minimal Myeloid Differentiation (FAB AML-M0): A Study of Eleven Cases. Leukemia and Lymphoma, 1993, 12, 103-108.	1.3	23
569	Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution.. Journal of Clinical Oncology, 1993, 11, 1661-1667.	1.6	70
570	Therapy-related acute promyelocytic leukemia: a report on 16 cases.. Journal of Clinical Oncology, 1992, 10, 1430-1435.	1.6	108
571	Prognostic factors in myelodysplastic syndromes. Leukemia Research, 1992, 16, 77-86.	0.8	47
572	PROGNOSTIC IRRELEVANCE OF CD34 IN ACUTE MYELOID LEUKAEMIA. British Journal of Haematology, 1992, 82, 480-480.	2.5	0
573	A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia.. Journal of Clinical Oncology, 1991, 9, 39-43.	1.6	49
574	PROGNOSTIC VALUE OF CD34 EXPRESSION IN DE NOVO ACUTE MYELOBLASTIC LEUKAEMIA. British Journal of Haematology, 1991, 79, 533-534.	2.5	32
575	Pregnancy outcome in hematologic malignancies. Cancer, 1991, 67, 703-709.	4.1	100
576	Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. British Journal of Haematology, 1990, 75, 26-33.	2.5	77

#	ARTICLE	IF	CITATIONS
577	TWO TYPES OF ACQUIRED IDIOPATHIC SIDEROBLASTIC ANAEMIA. British Journal of Haematology, 1990, 75, 633-634.	2.5	9
578	Acute Promyelocytic Leukaemia. Relationship of Cytochemical Pattern with Clinical, Morphologic and Immunological Characteristics, and Outcome. Leukemia and Lymphoma, 1990, 2, 85-92.	1.3	2
579	Validation of survival-predictive models in myelodysplastic syndromes. American Journal of Hematology, 1989, 30, 44-44.	4.1	0
580	n-th roots of a non-negative operator. Conditions for uniqueness. Manuscripta Mathematica, 1989, 64, 403-417.	0.6	4
581	Prognostic factors in chronic myelodysplastic syndromes: A multivariate analysis in 107 cases. American Journal of Hematology, 1988, 27, 163-168.	4.1	43
582	Essential thrombocythemia and pregnancy. American Journal of Hematology, 1988, 28, 66-66.	4.1	11
583	Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer, 1988, 61, 7-13.	4.1	126
584	MONOSOMY 7 AND ACUTE MIXED LEUKAEMIA. British Journal of Haematology, 1986, 64, 842-844.	2.5	8
585	Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer, 1985, 56, 2369-2375.	4.1	117
586	Successful Pregnancy during Chemotherapy for Acute Promyelocytic Leukemia. New England Journal of Medicine, 1982, 306, 939-939.	27.0	11
587	Bolus of Methylprednisolone for Aplastic Anemia. Annals of Internal Medicine, 1982, 96, 124.	3.9	3
588	Long-term Survival in Chronic Neutrophilic Leukemia. American Journal of Clinical Pathology, 1980, 74, 717.1-717.	0.7	3